Table 3 Novel therapeutics in Polycythemia Vera
From: Erythropoiesis: insights into pathophysiology and treatments in 2017
Company | Drug | Mechanism | Eligibility | Route | Clintrials.gov | Status |
|---|---|---|---|---|---|---|
Small molecules targets | ||||||
 Incyte Coproration Novartis | Jak 1/2 inhibitor (ruxolitinib) vs BAT | Cytoreduction | - age ≥ 18 years | Oral | NCT01243944 | Active, not recruiting - Phase 3 |
 Incyte | Jak 1/2 inhibitor (ruxolitinib) vs HU | Cytoreduction | - age ≥ 18 years | Oral | NCT01632904 | Completed - Phase 3 |
 AOP Orphan Pharmaceuticals AG | Pegylated interferon alpha-2b (AOP2014) vs HU | Cytoreduction | - age ≥ 18 years | subcutaneously | NCT01949805 | Completed - Phase 3 |
 Roskilde University Hospital, | Vorinostat | Cytoreduction | - age ≥ 18 years | Oral | – | Completed - Phase 2 |
 Italframaco | Givinostat vs HU | Cytoreduction | - age ≥ 18 years | Oral | NCT00928707 | Completed - Phase 2 |